Recombinant Human Interferon α2b

Developed for: herpangina · herpes zoster · respiratory syncytial virus bronchiolitis
Investigated by: Anhui Provincial Children's Hospital · Changhai Hospital · Children's Hospital of Chongqing Medical University · Children's Hospital of Fudan University · Children's Hospital of Kaifeng City · Hunan Children's Hospital
+6 more
· Lee's Pharmaceutical Limited · Qilu Children's Hospital of Shandong University · Shenzhen Children's Hospital · Tianjin Sinobioway Biomedicine Co.Ltd. · Yuying Children's Hospital of Wenzhou Medical University · Zunyi Medical College

today NCT05806918 · Ph 3 NCT03266601 · Ph 4

2017201820192020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 31 trial
Phase 3	NCT05806918	Apr → Jul 2023	herpes zoster	Lee's Pharmaceutical Limited	Unknown	No outcome recorded
Phase 41 trial
Phase 4	NCT03266601	Jun 2016 → Nov 2018	herpangina	Children's Hospital of Fudan University	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT06827249 Comparator	Mar 2025 → Jun 2026 overdue	respiratory syncytial virus bronchiolitis	Children's Hospital of Soochow University	Recruiting	No outcome recorded
—	NCT04273763 Background	Feb → May 2020	COVID-19	Second Affiliated Hospital of Wenzhou Medical University	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	recombinant human interferon α-2b	“recombinant human interferon α-2b” NCT06827249 ↗ 4 NCT05806918 ↗ NCT04273763 ↗ NCT06827249 ↗ NCT03266601 ↗
Known as	Jeferon	“Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and...” NCT03266601 ↗
Known as	Recombinant Human Interferon alpha 2b	“Recombinant Human Interferon alpha 2b, at a dose of 100,000 IU/kg” NCT06827249 ↗
Known as	ZK-A03	“The goal of this clinical trail is to demonstrate the non-inferiority of recombinant human interferon α-2b gel (ZK-A03) after changing the manufacturer of the active ingredient...” NCT05806918 ↗
Modality	Protein / enzyme biologic	“Recombinant human interferon α-2b spray” NCT03266601 ↗
Route	Other	“Recombinant human interferon α-2b spray” NCT03266601 ↗